AKT Inhibitors – Targeting PI3K/AKT/MTOR Signaling Axis - Cora Sternberg
Interviews

AKT Inhibitors – Targeting PI3K/AKT/MTOR Signaling Axis - Cora Sternberg

Beyond androgen blockade: new pathways and novel treatments in mHSPC and mCRPC

In this interview for UroToday dr. Cora Sternberg presents the latest data and ongoing clinical trials in the context of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).

Go to the video

SAMUEL AND BARBARA STERNBERG ETS FOUNDATION

MORE ARTICLES